This week has been a wild ride, but it has been a week full of recovery in stocks versus last week’s panic selling with broken market efficiencies. The bull market is now just three weeks shy of being nine years old, and the one trend that has served investors huge rewards for over five years now has been to buy the pullbacks. Investors still have to decide how they want to be positioned for 2018 and beyond.
24/7 Wall St. reviews dozens of analyst research reports each day of the week to find new ideas for investors and traders alike. Some analyst reports and research reports cover stocks to buy. Others cover stocks to sell or to avoid.
Additional color and commentary has been added on most of the daily analyst reports. The consensus analyst price targets and other valuation metrics are from the Thomson Reuters sell-side research service.
These were the top analyst upgrades, downgrades and other research calls from Thursday, February 15, 2018.
AMAG Pharmaceuticals Inc. (NASDAQ: AMAG) has received FDA approval now for a new subcutaneous version of Makena, and shares were indicated up almost 20% at $16.65 on the news. Janney raised its rating to Buy with a fair value range of $20 to $22, and the FDA approval slammed the door on the worst case scenario for its outlook, according to the firm.
Baidu Inc. (NASDAQ: BIDU) was raised to Overweight from Equal Weight with a $280 price target (versus a $225.60 close) at Morgan Stanley. Baidu has a 52-week trading range of $166.00 to $274.97 and a consensus analyst price target of $267.93.
BJ’s Restaurants Inc. (NASDAQ: BJRI) was raised to Outperform from Neutral with a $44 price target (versus a $37.60 close) at Wedbush Securities.
Box Inc. (NYSE: BOX) was started as Buy and assigned a $25 price target (versus a $21.20 close) at D.A. Davidson. It has a 52-week range of $15.73 to $24.10 and a consensus price target of $25.27.
Bristol-Myers Squibb Co, (NYSE: BMY) was raised to Overweight from Equal Weight at Morgan Stanley. The 52-week range is $51.56 to $66.10, and the consensus price target is $64.18.
CEMEX SAB de C.V. (NYSE: CX) was downgraded to Sell from Buy with a $6.50 price target (versus a $7.62 close) at UBS. Its 52-week range is $7.10 to $10.37, but the American depositary shares were indicated down 4.35 at $7.27 on Thursday morning.
Cisco Systems Inc. (NASDAQ: CSCO) closed up 2.1% at $42.09 ahead of earnings and was last seen up 7.9% at $45.40 on Thursday morning after earnings. Oppenheimer maintained its Outperform rating and raised its target to $50 from $46. Cisco already has seen many upgrades and higher target prices in 2018.
Compass Minerals International Inc. (NYSE: CMP) was downgraded to Underperform from Neutral at Credit Suisse. Shares closed down 2.17% at $67.75 on Wednesday, in a 52-week range of $59.72 to $79.45.
Credit Suisse A.G. (NYSE: CS) was raised to Buy from Hold at Societe Generale.
Eaton Corp. (NYSE: ETN) was started as Equal Weight and assigned a $90 price target at Barclays.
Emerson Electric Co. (NYSE: EMR) was started as Overweight and assigned an $80 price target at Barclays. It has a 52-week range of $56.77 to $74.45 and a consensus target price of $72.00.
Foundation Medicine Inc. (NASDAQ: FMI) was started as Outperform with a $90 price target (versus a $65.60 close) at Cowen. The stock was indicated up 2% at $66.95 after the call, in a 52-week range of $22.40 to $75.20 and with a prior consensus target price of $58.50.
Follow @Jonogg on Twitter to receive the daily analyst calls and other market research calls directly on your feed.